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background: Prevalence and outcomes of patients who are on chronic Vitamin K antagonist therapy (VKA) in acute STEMI populations are largely 
unknown as they were excluded from prospective clinical trials. It is unclear whether chronic VKA is associated with increased longterm mortality.
methods: In a large academic center, all patients who presented with STEMI between 1/1/2009 and 31/12/2010 were studied. Demographic, 
past medical and lab data was electronically queried. Medications and clinical outcomes were manually reviewed. All-cause mortality was obtained 
from Social Security Death Master File updated until 3/31/2013.
results: Out of 628 patients with STEMI, 21 (3.3%) were on VKA on admission. Mean INR between non-VKA and VKA groups was 1.2±0.3 vs. 
2.6±1.0, p<0.01. None had reversal of INR prior to PCI and there was no difference in door to balloon time between 2 groups. Total of 71 (11.3%) 
patients died during study period, 6 (29%) in VKA and 65 (11%) in non-VKA group (p=0.01). See Figure 1 for KM survival curves showing effect 
of VKA on mortality. Cox-proportional hazards models showed that delay in PCI, peripheral vascular disease, EF and VKA therapy were significant 
predictors of mortality but not antiplatelet use, revascularization methods and bleeding complications (Table1).
Conclusions: In patients with acute STEMI, prevalence of VKA use is 3.3%. Chronic VKA therapy is an independent risk factor for mortality in 
patients with STEMI and specific strategies may be needed to address the excess risk.
 
